Proprietary AI analyst is now available
- Public Comps
- Integral Diagnostics
Integral Diagnostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Integral Diagnostics and similar public comparables like Strata Critical Medical, Garofalo Health Care, Fulgent Genetics, Al-Maidan Dental Clinic and more.
Integral Diagnostics Overview
About Integral Diagnostics
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
Founded
2008
HQ

Employees
3.0K
Website
Financials (LTM)
EV
$945M
Valuation Multiples
Start free trialIntegral Diagnostics Financials
Integral Diagnostics reported last 12-month revenue of $560M and EBITDA of $117M.
In the same LTM period, Integral Diagnostics generated $544M in gross profit, $117M in EBITDA, and $34M in net income.
Revenue (LTM)
Integral Diagnostics P&L
In the most recent fiscal year, Integral Diagnostics reported revenue of $447M and EBITDA of $78M.
Integral Diagnostics is profitable as of last fiscal year, with gross margin of 96%, EBITDA margin of 17%, and net margin of 5%.
Financial data powered by Morningstar, Inc.
Integral Diagnostics Stock Performance
Integral Diagnostics has current market cap of $540M, and enterprise value of $945M.
Market Cap Evolution
Integral Diagnostics' stock price is $1.45.
Integral Diagnostics share price decreased by 7.3% in the last 30 days, and by 19.8% in the last year.
Integral Diagnostics has an EPS (earnings per share) of $0.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $945M | $540M | -2.0% | -7.3% | -14.5% | -19.8% | $0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIntegral Diagnostics Valuation Multiples
Integral Diagnostics trades at 1.7x EV/Revenue multiple, and 8.1x EV/EBITDA.
EV / Revenue (LTM)
Integral Diagnostics Financial Valuation Multiples
As of June 5, 2026, Integral Diagnostics has market cap of $540M and EV of $945M.
Integral Diagnostics has a P/E ratio of 15.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Integral Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Integral Diagnostics Margins & Growth Rates
Integral Diagnostics grew revenue by 28% and EBITDA by 54% in the last fiscal year.
In the most recent fiscal year, Integral Diagnostics reported gross margin of 96%, EBITDA margin of 17%, and net margin of 5%.
Integral Diagnostics Margins
Integral Diagnostics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Integral Diagnostics Operational KPIs
Integral Diagnostics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Integral Diagnostics' Rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Integral Diagnostics' Rule of X is 61% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Integral Diagnostics Competitors
Integral Diagnostics competitors include Strata Critical Medical, Garofalo Health Care, Fulgent Genetics, Al-Maidan Dental Clinic, Chularat Hospital, Assure Tech, Jiangsu Bioperfectus, Indisa, Sikarin and Myriad Genetics.
Most Integral Diagnostics public comparables operate across Hospitals & Clinics, Laboratory Services, Medical Imaging & Diagnostics and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.5x | 2.1x | 34.7x | 23.5x | |||
| 1.4x | 1.3x | 8.2x | 8.2x | |||
| 0.9x | 0.9x | (28.7x) | (9.8x) | |||
| 1.6x | - | 8.8x | - | |||
| 1.7x | 1.7x | 8.0x | 8.0x | |||
| 5.2x | - | 19.0x | - | |||
| 8.8x | - | 90.4x | - | |||
| 1.8x | - | 15.5x | - | |||
This data is available for Pro users. Sign up to see all Integral Diagnostics competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Integral Diagnostics
| When was Integral Diagnostics founded? | Integral Diagnostics was founded in 2008. |
| Where is Integral Diagnostics headquartered? | Integral Diagnostics is headquartered in Australia. |
| How many employees does Integral Diagnostics have? | As of today, Integral Diagnostics has over 3K employees. |
| Who is the CEO of Integral Diagnostics? | Integral Diagnostics' CEO is Ian Kadish. |
| Is Integral Diagnostics publicly listed? | Yes, Integral Diagnostics is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Integral Diagnostics? | Integral Diagnostics trades under IDX ticker. |
| When did Integral Diagnostics go public? | Integral Diagnostics went public in 2015. |
| Who are competitors of Integral Diagnostics? | Integral Diagnostics main competitors include Strata Critical Medical, Garofalo Health Care, Fulgent Genetics, Al-Maidan Dental Clinic, Chularat Hospital, Assure Tech, Jiangsu Bioperfectus, Indisa, Sikarin, Myriad Genetics. |
| What is the current market cap of Integral Diagnostics? | Integral Diagnostics' current market cap is $540M. |
| What is the current revenue of Integral Diagnostics? | Integral Diagnostics' last 12 months revenue is $560M. |
| What is the current revenue growth of Integral Diagnostics? | Integral Diagnostics revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Integral Diagnostics? | Current revenue multiple of Integral Diagnostics is 1.7x. |
| What is the current EBITDA of Integral Diagnostics? | Integral Diagnostics' last 12 months EBITDA is $117M. |
| What is Integral Diagnostics' EBITDA margin? | Integral Diagnostics' last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Integral Diagnostics? | Current EBITDA multiple of Integral Diagnostics is 8.1x. |
| What is the current FCF of Integral Diagnostics? | Integral Diagnostics' last 12 months FCF is $34M. |
| What is Integral Diagnostics' FCF margin? | Integral Diagnostics' last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Integral Diagnostics? | Current FCF multiple of Integral Diagnostics is 28.1x. |
| How many companies Integral Diagnostics has acquired to date? | Integral Diagnostics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Integral Diagnostics has invested to date? | Integral Diagnostics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Integral Diagnostics
Lists including Integral Diagnostics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.